OCX

Oncocyte Corporation · NASDAQ

Sector Health Technology
Industry Biotechnology
Website oncocyte.com
Employees(FY) 75
ISIN US68235C2061

Performance

-8.33%

-12.14%

-12.42%

-6.14%

+10.0%

YTD

-30.56%

Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Advanced Technical Analysis

Technical Analysis of OCX 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance. The Technical Score of 33 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of OCX

Stock Rank

Recent News & Updates

2024-11-12 13:21
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ...(Yahoo Finance)
2024-11-12 03:05
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025(Globenewswire)
2024-11-06 03:45
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12(Globenewswire)
2024-10-16 04:15
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles(Globenewswire)
2024-10-07 20:30
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial(Globenewswire)
2024-10-03 18:28
OncoCyte Secures Funding Through Private Share Sale(Yahoo Finance)
2024-10-02 06:41
Oncocyte Signs Leading Transplant Centers in US and Germany(Globenewswire)
2024-10-02 06:35
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules(Globenewswire)
2024-08-19 21:00
PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology(Globenewswire)
2024-08-12 04:10
Oncocyte's VitaGraft Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study(Globenewswire)
2024-08-08 04:05
Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results(Globenewswire)
2024-08-05 04:05
Oncocyte Announces August Investor Conferences Participation(Globenewswire)
2024-08-01 04:05
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8(Globenewswire)
2024-07-10 20:00
MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in 'Take Advantage of the Moment' Episode(Globenewswire)
2024-06-24 00:41
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move(Globenewswire)
2024-06-17 04:05
Oncocyte Appoints Andrea James as Chief Financial Officer(Globenewswire)
2024-06-04 19:00
OncoCyte's Innovative Approach: Potential in Precision Diagnostics(Newsdirect)
2024-06-03 02:13
Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study(Globenewswire)
2024-05-30 04:47
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine(Globenewswire)
2024-05-15 08:55
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-15 04:05
Oncocyte Reports First Quarter 2024 Financial Results(Globenewswire)
2024-05-12 20:00
Oncocyte to Announce First Quarter 2024 Financial Results(Globenewswire)
2024-05-06 21:19
PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace(Globenewswire)
2024-04-11 22:52
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023(Investorplace)
2024-04-11 18:00
Oncocyte Reports Full Year 2023 Financial Results(Globenewswire)
2024-04-11 09:46
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules(Globenewswire)
2024-04-11 05:30
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay(Globenewswire)
2024-04-09 04:05
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results(Globenewswire)
2024-01-15 19:00
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico(Globenewswire)
2023-12-05 19:00
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.